Spencer Tong is an analyst on the Seligman Healthcare Spectrum team at Columbia Threadneedle Investments. In this role, he covers the healthcare sector as a biotech (therapeutics) analyst. He joined the firm in the year 2025 and has been a part of the investment community since 2019. Previously, Spencer worked as an analyst at Walleye Capital where he focused primarily on the biotech (therapeutics) sector. Spencer earned a B.A. from Washington University in St. Louis and a DPhil (PhD) in medical sciences from the University of Oxford.